
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing sulfasalazine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing sulfasalazine are listed in tablet form. No finished sulfasalazine product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Sulfasalazine is an anti-inflammatory sulfa drug taken by mouth for ulcerative colitis and arthritis that a pharmacy may compound when a prescriber orders it.
Sulfasalazine joins a sulfonamide, sulfapyridine, to 5-aminosalicylic acid (5-ASA, mesalamine) through an azo bond. Little is absorbed in the upper gut; bacteria in the lower bowel split the bond, releasing 5-ASA, which acts locally to calm intestinal inflammation, and sulfapyridine, which is absorbed. Manufactured products are Azulfidine tablets and Azulfidine EN-tabs delayed-release tablets, plus generics. Both are indicated for mild to moderate ulcerative colitis, as add-on therapy in severe ulcerative colitis, and to lengthen remission between attacks. EN-tabs are also indicated for rheumatoid arthritis and polyarticular-course juvenile rheumatoid arthritis that responded inadequately to salicylates or other NSAIDs. MedlinePlus notes use for Crohn's disease, which is not an FDA-approved indication. A prescriber might order sulfasalazine compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Sulfasalazine labels carry no boxed warning, but deaths have been reported from allergic reactions, severe blood disorders (agranulocytosis, aplastic anemia), liver and kidney damage, nerve changes and lung scarring. Serious infections, DRESS and severe skin reactions such as Stevens-Johnson syndrome can occur. Do not take it with a sulfa or salicylate (aspirin) allergy, a bowel or urinary blockage, or porphyria. Use caution with asthma or G6PD deficiency. It can reduce absorption of folic acid and digoxin. Drink plenty of fluids, take it after meals, and expect possible orange-yellow urine or skin; MedlinePlus advises limiting sun exposure. It can lower sperm counts, which reverses after stopping. The label advises use in pregnancy only if clearly needed and notes its effect on folic acid. LactMed calls it low risk in breastfeeding but advises watching the infant for diarrhea. Call your prescriber right away about sore throat, fever, pale skin, unusual bruising, yellow skin or eyes, or a rash.
The mode of action of sulfasalazine or its metabolites 5-ASA and sulfapyridine may relate to anti-inflammatory and immunomodulatory properties seen in animal and in vitro models. Absolute oral bioavailability of parent drug is under 15%; colonic bacteria cleave it to sulfapyridine (bioavailability about 60%) and 5-ASA (about 10% to 30%). Sulfasalazine is over 99.3% albumin bound, sulfapyridine about 70%. Plasma half-life of intravenous sulfasalazine is 7.6 hours; sulfapyridine is acetylated, with a half-life of 10.4 hours in fast and 14.8 hours in slow acetylators. Most 5-ASA stays in the colon and is excreted in feces; absorbed metabolites are excreted in urine. Labeled indications: Azulfidine tablets (NDA007073) for ulcerative colitis; Azulfidine EN-tabs (NDA007073) for ulcerative colitis, rheumatoid arthritis and polyarticular-course juvenile rheumatoid arthritis. MedlinePlus lists Crohn's disease as an off-label use. LiverTox describes a rare, idiosyncratic hypersensitivity liver injury, usually within 2 to 6 weeks of starting. Dosing is per prescriber. The label calls for complete blood counts with differential and liver tests before starting and on a set schedule thereafter, plus urinalysis and renal function checks. Sulfasalazine is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally